Triple-action diabetes jab shown to reduce blood sugar and body weight
Retatrutide is designed to control appetite and blood sugar but also increase body’s energy expenditure, unlike other drugs A new triple-action weekly jab for type 2 diabetes could significantly reduce blood sugar and body weight, according to phase 3 trial results . Patients in the trial receiving weekly retatrutide injections for 40 weeks lost more than four times as much weight as those on placebo, while the average drop in long-term blood sugar (HbA1c) was more than twice
A new weekly injection called retatrutide has demonstrated significant reductions in both blood sugar levels and body weight in patients with type 2 diabetes. In a recent phase 3 trial, participants receiving the drug for 40 weeks experienced substantial weight loss, exceeding four times that of the placebo group. Additionally, the treatment led to a more than twofold greater decrease in long-term blood sugar (HbA1c) compared to placebo.
Retatrutide functions by mimicking three key gut hormones—GLP-1, GIP, and glucagon—to regulate appetite, blood sugar, and metabolism. This triple-action mechanism sets it apart from existing diabetes medications, as it additionally targets the glucagon receptor to boost the body's energy expenditure.
This development offers a promising new therapeutic option for managing type 2 diabetes and obesity, potentially addressing multiple aspects of the disease simultaneously.
📌 Kaynak
Bu özet Guardian World kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →